P
ProHub
English 简体中文 繁體中文
Medium Growth Strategy Profitability

The Pill Company

#Healthcare
ProHub Comment

This is a strong medium-difficulty case that tests candidates' ability to structure a declining business problem using MECE frameworks, perform quantitative analysis on patent expiration impact, and make strategic tradeoff decisions under uncertainty. The case progresses from diagnosis (identifying Green Pill as the largest revenue driver) to strategic evaluation (Do Nothing vs. License options), requiring both analytical rigor and strategic thinking about long-term implications.

Estimated Time 26 minutes
Difficulty Medium
Source Duke
10 / 100
Your client is a multinational pharmaceutical company. The client has a portfolio of drugs for major disease areas, including cancer, cardiovascular, and gastrointestinal diseases. The client has experienced a decline in revenue over the last 18 months, and is fearful of further declines, especially given that its most commercially successful drug, which treats acid reflux, a gastrointestinal disease, will be going off patent in the next year. What are the areas they should investigate to change the course of this trend?

Clarifying Information

  1. Geography: Multinational company (stated in first line); can think of PillCo. like a GSK or AZ that operates around the world
  2. Product Mix: Current disease areas includes Neuroscience, Respiratory, Gastrointestinal, and Cardiovascular
  3. Each disease area includes a portfolio of drug products
  4. Business model: like that of a typical large pharmaceutical company producing brand name drugs from in-house R&D to a commercial sales teams that sell through typical channels with doctors needing to prescribe the drug
  5. Competition: Generic companies will be new competitors
  6. In addition to other issues, the decline is attributed to the introduction of generics in the US and other established markets. It’s fair to attribute 50% of the decline to generics. The additional declines were related to Medicaid liability and other inventory related issues.
Mock Interview
Interviewer

Your client is a multinational pharmaceutical company. The client has a portfolio of drugs for major disease areas, including cancer, cardiovascular, and gastrointestinal diseases. The client has experienced a decline in revenue over the last 18 months, and is fearful of further declines, especially given that its most commercially successful drug, which treats acid reflux, a gastrointestinal disease, will be going off patent in the next year. What are the areas they should investigate to change the course of this trend?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

A multinational pharmaceutical company faces an 18-month revenue decline driven primarily by generic competition and pending patent expiration. Candidates must diagnose root causes using product mix and market analysis, quantify the impact of patent loss, and evaluate two strategic options (maintain brand vs. license to OTC) for the Purple Pill, considering both short-term gains and long-term revenue sustainability.

Key Insights:

  1. Use MECE framework covering Product Mix, Market/Competition, and Growth Levers (Build/Buy/Partner) to structure the declining revenue problem
  2. Patent expiration is a critical driver—generic competition typically captures 50% volume share, significantly reducing profitability despite maintaining some market presence
  3. Quantitative analysis requires reverse-engineering historical revenues from percentage declines (new/old - 1 = % change formula) to identify Green Pill as the $1B revenue loss driver
  4. Strategic decision-making must balance short-term revenue gains (licensing upfront $1B payment) against long-term sustainability (Do Nothing generates $2.5B vs. License’s $2.25B over 2 years)
  5. Cannibalization risk and long-term brand equity degradation are often more strategically important than immediate financial gains, requiring candidates to think beyond the mathematics
  6. In pharmaceutical context, generic entry creates a permanent structural change requiring portfolio rebalancing and new product development investment